Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)
This study has been completed.
First Posted: September 12, 2005
Last Update Posted: November 2, 2011
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )